Precede Biosciences Funding: $84M Raised, Series B (2026)
Precede Biosciences is based in Boston. It has raised $84M in total funding. Latest round: Series B.
Precede Biosciences funding overview
Precede Biosciences is based in Boston. Precede Biosciences has raised $84M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in January 2026. The round record for Precede Biosciences runs through 2026; nothing later has been disclosed. Investors on record include 5AM Ventures, Lilly Asia Ventures, Illumina Ventures, Bristol Myers Squibb, Osage University Partners, Qatar Investment Authority and 4 others. 10 distinct backers are named across the disclosed rounds.
Frequently asked about Precede Biosciences funding
How much has Precede Biosciences raised?
Precede Biosciences has raised $84M in total disclosed funding across the rounds on record.
Who has invested in Precede Biosciences?
5AM Ventures, Lilly Asia Ventures, Illumina Ventures, Bristol Myers Squibb, Osage University Partners, Qatar Investment Authority are named among the investors backing Precede Biosciences.
What was the latest Precede Biosciences funding round?
The most recent disclosed round is a Series B, announced in January 2026.
Where is Precede Biosciences based?
Precede Biosciences is based in Boston.
When did Precede Biosciences last raise?
The last disclosed Precede Biosciences round closed in January 2026 at Series B.
Every Precede Biosciences figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Boston at a similar stage.
